Short report

The effect of deletion of the orphan G – protein coupled receptor (GPCR) gene MrgE on pain-like behaviours in mice

Peter J Cox*1, Tom Pitcher1, Steven A Trim1, Christine H Bell1, Wenning Qin2 and Ross A Kinloch1

Address: 1Pain Therapeutics, Discovery Biology, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, UK and 2Genetically Modified Models Centre of Emphasis, Pfizer Global Research and Development, MS 8118D-3110, Eastern Point Road, Groton, CT 06340, USA

Email: Peter J Cox* - Peter.J.Cox@pfizer.com; Tom Pitcher - Tom.Pitcher@pfizer.com; Steven A Trim - Steven.Trim@pfizer.com; Christine H Bell - Christine.H.Bell@pfizer.com; Wenning Qin - Wenning.Qin@pfizer.com; Ross A Kinloch - Ross.Kinloch@pfizer.com

* Corresponding author

Abstract

Background: The orphan GPCR MrgE is one of an extended family of GPCRs that are expressed in dorsal root ganglia (DRG). Based on these expression patterns it has been suggested that GPCRs like MrgE may play a role in nociception however, to date, no direct supporting evidence has emerged. We generated mutant mice lacking MrgE and examined the effects of deletion of this gene in three pain behavioural models. The effect of MrgE gene deletion on expression of Mrgs and genes involved in sensory neurone function was also investigated.

Results: The absence of MrgE had no effect on the development of pain responses to a noxious chemical stimulus or an acute thermal stimulus. However, in contrast, the development but not the maintenance of neuropathic pain was affected by deletion of MrgE. The expression of MrgE genes was not significantly affected in the MrgE knockout (KO) mice with the sole exception of MrgF. In addition, the expression of 77 of 84 genes involved in sensory neuron development and function was also unaffected by deletion of MrgE. Of the 7 genes affected by MrgE deletion, 4 have previously been implicated in nociception.

Conclusion: The data suggests that MrgE may play a role in selective pain behavioural responses in mice.

Background

Mrg-receptors, first described in 2001 [1], constitute a family of G-protein coupled receptors in which certain members are expressed in distinct subsets of sensory neurones, known to play a role in nociception, and were activated by peptides that had previously been functionally linked to pain. Indirect physiological evidence for a role for MrgC, in particular, was provided by the demonstration that peptides known to activate MrgC elicited pain-like behaviours on administration to rats [2]. Recently it has been shown that levels of one of these peptides, Bovine Adrenal Medulla peptide 22, was increased in superficial laminae of the spinal cord (SC) and in DRG cells following complete freunds adjuvant induced inflammation [3]. However the specificity of these peptides for MrgC has not been conclusively demonstrated, therefore non-MrgC mediated effects cannot be ruled out. Expression of rat MrgC and MrgA is down regulated in
DRG following spinal nerve ligation provided additional evidence that these receptors are somehow functionally linked to pain [4]. Elegant studies with genetically modified mice demonstrated that MrgD is uniquely expressed in primary afferent nerve fibres but pain behavioural phenotypes for mice lacking this receptor were not reported [5]. The MrgD ligand, beta-alanine, inhibited potassium channel mediated M-current activity in both a recombinant cell system and primary DRG neurons suggesting that activation of MrgD could inhibit the M-current resulting in repetitive firing of normally phasic nociceptive neurons leading to pain [6]. Similarly activation of MrgX1 expressed in rat superior cervical ganglion neurons resulted in M-current inhibition [7].

A functional role for Mrg receptors in other systems could be assumed from the physiological functions of ligands known to activate these receptors. MrgX2 is activated by basic molecules [8] and cortistatin [9], amongst other ligands, and is therefore postulated to have a role in mast cell degranulation and neuroendocrine function respectively. Murine MrgA1 and MrgC11 are activated by RF-amide peptides [10] suggesting that these receptors could be involved in a variety of neuromodulatory functions attributed to these peptides [11]. However, as with pain, direct physiological proof for a role for these receptors in these systems is lacking.

Study of members of this family is generally hampered by the lack of specific ligands and/or pharmacological tools. MrgE is an orphan receptor; however we and others have demonstrated that this receptor is largely restricted to the nervous system with greatest expression in SC and DRG [12]. In the absence of suitable tools we have developed genetically modified mice lacking MrgE. The phenotype of MrgE KO mice was studied in a number of assays, with particular focus on pain behaviours. The effect of deletion of MrgE on expression of a selection of genes known to be expressed in sensory neurons, including other Mrgs, was also investigated.

Results

Generation of MrgE KO mice

MrgE KO mice were generated using a standard homologous recombination strategy. Southern blot confirmed homologous recombination had occurred (data not shown) and a PCR genotyping strategy was used to genotype mouse tail DNA samples (see Fig. 1). The genotype of the MrgE KO animals was confirmed by absence of detectable MrgE transcripts in all tissues tested. TaqMan quantitative PCR confirmed the presence of MrgE expression in DRG, SC and brain from wild-type (WT) mice; whereas MrgE expression was not detected in homozygote MrgE KO mice (see Fig. 2).

Behavioural testing of KO and WT mice

KO and WT mice were subjected to a battery of behavioural and biochemical tests. KO mice appeared to be normal in the majority of tests with some minor differences noted in blood biochemistry, sexual behaviour and prepulse startle responses. However no overt phenotypic abnormalities were identified (Data not shown).

The locomotor activity of mice was assessed demonstrating no difference in the general motor coordination of WT and KO mice (see Fig. 3).

Intraplantar injection of formalin resulted in a biphasic nocifensive response in both WT and MrgE KO mice (see Fig. 4). There was a trend towards reduced nocifensive behaviours in the KO mice in the first phase of the response to formalin (see Fig. 4C); however this did not reach statistical significance. Overall, no significant difference in the frequency or timing of nocifensive behaviours between WT and KO mice was detected in either the first or second phase of the formalin test. Likewise, hotplate
responses of WT and KO mice were similar (data not shown).

KO and WT mice developed ipsilateral punctate allodynia after chronic constriction injury (CCI) of the sciatic nerve. A statistically significant difference in the rate of development of allodynia was demonstrated between WT and MrgE KO mice (see Fig. 5). The onset of maximal allodynia was delayed in the KO in comparison to the WT mice, with the most significant difference in allodynia noted in the day 2 to 7 period post surgery. Otherwise, the WT and MrgE KO mice maintained a similar level of allodynia indicated by a paw withdrawal threshold of 0.04 g or less. The onset of recovery at approximately 100 days post surgery was also similar in both groups.

**Gene expression analysis**

The expression of Mrg gene family members together with genes important for sensory neuron function and development were examined in various tissues from adult WT and MrgE KO mice by quantitative RTPCR analysis. In WT animals, MrgD and E are the most abundant Mrgs in DRG (see Fig. 2A); whereas MrgE is the most abundant Mrg in SC and brain with 6000 and 3000 arbitrary copies respectively (see Fig. 2B). There is no statistical difference in the expression of MrgC11, D, F, G, H and PR4 genes in DRG of KO and WT mice. However, MrgF is up-regulated 2-fold (p = 0.0013) in the SC of KO animals (see Fig. 2B). MrgC11 and D expression was detected at extremely low levels in brain and SC preparations from some, but not all, mice while MrgPRa4 or MrgG expression was not

---

**Figure 2**

Quantitative RTPCR analysis of Mrg expression. Quantitative RTPCR analysis of Mrg expression in (A) DRG and (B) SC and brain from WT and KO mice. The asterisks indicate that no copies of MrgE were detected.

**Figure 3**

Locomotor activity of WT and KO mice. Data is Mean ± SEM of 3–4 mice per group expressed as activity counts per 5 minute bin intervals for 1 hour. No significant effect was seen between the groups over the time course.
detected in brain or SC (data not shown). Use of the RT^2 PCR profiler array (SuperArray) consisting of genes implicated in patterning, development and/or function of sensory neurones revealed a trend towards reduced expression of GFRα-2, Nav1.7, Nav1.8, and Runx-1 in DRG from KO versus WT mice (see Fig. 6) (p = <0.05, p = *0.07).

The effect of chronic constriction injury of the sciatic nerve on MrgE gene expression was examined in the rat. Expression of MrgE in the injured sciatic nerve relative to the uninjured sciatic nerve was significantly reduced at all time points post surgery tested (see Fig. 7).

Discussion
MrgE KO and WT mice are indistinguishable in the formalin and hotplate tests implying that MrgE plays no significant role in the response to noxious chemical and thermal stimuli respectively. Dong et al 2001 demonstrated that MrgD and MrgA1 are expressed in vanniloid receptor-1 (VR1) negative small diameter sensory neurones in the mouse, indicating that these receptors may be less important for the detection of noxious chemical stimuli. At present the detailed distribution of other Mrgs, including MrgE, in rodent DRG has not been determined. Taken together, the KO and distribution data would suggest that Mrgs, in general, may not be involved in the sensing of chemically induced pain, although this may not be the case for higher mammals where distribution of MrgD and E in VR1 positive and medium to large diameter neurones, respectively, was detected in DRG [13].

There was a significant difference between WT and KO mice in the rate they develop an increased hypersensitivity to the application of von Frey hairs. However the peak level of allodynia acquired, and maintained, was similar in both WT and KO mice. The slower rate of onset of allo-

---

Figure 4
Formalin test of WT and MrgE KO mice. (A) The time course of development of formalin responses in KO and WT mice. (B) The early and late phase of the formalin response in KO and WT mice showing a trend towards reduction in early phase behaviours in KO mice.

Figure 5
Chronic constriction injury of WT and MrgE KO mice. The punctuate allodynia data are expressed as median force (g) required to induce a PWT in wild-type (n = 13) and KO (n = 6) mice (vertical bars represent the first and third quartiles). "+++P < 0.01, *P < 0.05 unpaired T Test comparing WT and KO mice at each time point.

Figure 6
Quantitative RTPCR analysis of DRG expression of genes involved in sensory neuron function in WT and KO mice. RT2 arrays revealed several sensory neurone genes were reduced in DRG of the KO relative to WT animals (p = <0.05, p = *0.07). Error bars represent standard deviation.
Dynia in the KO animals suggests that MrgE plays a role in the development but not the maintenance of allodynia. Whether this behavioural effect is directly due to lack of functional MrgE in adult mice or has arisen due to the absence of MrgE during the development of the nervous system in KO animals remains to be seen. In the adult rat MrgE expression is significantly reduced as early as day 7 post CCI of the sciatic nerve lending further support to the notion that this gene may be involved in the development of allodynia. Down regulation of MrgE or a reduction in cells expressing MrgE may be an essential component of the temporal processes that affect the development of allodynia, therefore the complete absence of this gene deregulates these processes slowing the development of allodynia in the KO mice.

Emerging data and hypotheses suggest that cellular and functional plasticity involving neuro-immune interaction and neuronal long term facilitation, potentiation and depression in the periphery, at spinal and/or supraspinal sites may underlie behaviours such as allodynia associated with persistent pain states (For recent reviews see [14,15]). Although Mrge is expressed at all tissue levels known to be involved in pain sensation, the KO data suggests that it has no role in maintaining the long term plastic changes that may underlie neuopathic pain. This notion is supported by the observation that KO and WT animals develop the same degree of allodynia.

The small but statistically significant down regulation of genes known to be involved in sensory neuron function and development is of interest and may also offer an explanation. It is tempting to speculate that reduction in the expression of these genes observed in the DRG of KO mice may reflect a reduction in the number of neurons that express these same genes. The loss of these sensory neurons may result in the observed deficit in the rate of development of alldynia. Deficits in pain-like behaviours have been demonstrated in GFR α-2 [16] Na1.7 [17]Na1.8 [18,19] and Runx-1 [20] KO mice, although the extent and nature of these behavioural deficits are much more dramatic than those demonstrated with the MrgE KOs, possibly because of complete loss of expression of the genes under study.

The expression of only one Mrg, MrgF was shown to be altered by MrgE deletion. MrgD gene expression was unaffected by MrgE deletion although both these receptors have been shown to functionally associate in a recombinant cell system [12]. Although speculative, upregulation of MrgF may compensate for the absence of MrgE therefore it would be interesting to determine if co-expression of MrgF had any effect on MrgD function, or if the pain behavioural phenotype of an MrgF MrgE double KO would be more profound than that observed with MrgE KOs.

**Conclusion**

The data presented in this paper is the first to demonstrate a role for the orphan GPCR MrgE in pain. The functional significance of MrgE deletion on pain will require extension of these studies to detailed molecular and immunohistochemical analysis of the KO mice, and further analysis of the effects of MrgE gene deletion on other pain endpoints and in other pain models.

**Methods**

**Generation of MrgE KO mice**

MrgE targeted ES clone was obtained from Deltagen (San Carlos, CA.). A genomic fragment containing the MrgE gene was isolated from a mouse genomic phage library. The targeting vector was assembled on the pGT-N28 backbone (NEB, Ipswich, MA) and so designed that a total of 776 bps from within the 930 base pair coding region located in exon 2 of MrgE gene (first exon is un-translated) was deleted and replaced with a 7,076 bp IRES-lacZ reporter and neomycin resistance cassette (IRES-lacZ-NEO) (see Fig. 1A). The targeting vector was linearized and electroporated into the E14 (129/Ola) mouse embryonic stem (ES) cells. ES cells were then cultured in the presence of the antibiotic G418/geneticin, and surviving colonies carrying the homologously integrated neo DNA were identified by PCR amplification, retrieving a 6.5 kb fragment, using a neo-specific reverse primer (5'-ATCAGCTTACCAGCCAAGATCCC-3') paired with a forward primer located 5' to the 5' homology arm (5'-GACATCTCCCTAGTCCAGACGACTC-3'). Successful homologous recombination at the 3' end was also confirmed using a neo-specific forward primer.
product is 201 and mutant allele 922 bps (see Fig. 1B). (5’-ATC TAT CTC TTG GAT GTG GCC TG-3’). The WT

thetic chamber and anaesthetised with a 2% isofluorane

lowing CCI of the right sciatic nerve based on previously

Neuropathic pain behaviours in mice were assessed fol-

5-minute bins for 45 minutes following formalin injec-

were habituated to perspex boxes for 15 minutes before

test as follows. Homozygote KO mice and WT littermates

domly placed in the photo beam equipped cages. Activity data was captured on computer. Mice were ran-

recorded as activity counts as the beams were broken. Centre of the cage and total locomotor activity (ambula-

Molecular Pain 2008, 4:2 http://www.molecularpain.com/content/4/1/2

O2 mixture. The right hind thigh was shaved and swabbed

withdrawal threshold (PWT) in grams. Static allodynia

force required to elicit a response was recorded as paw

withdrawal response was established, the paw was re-tested,

starting with the filament below. The lowest amount of

force required to elicit a response was recorded as paw

withdrawal threshold (PWT) in grams. Static allodynia

was defined as present if animals responded to a force
equal to or less than, 0.04 g, which is innocuous in nor-

othermic blanket for the duration of the procedure and

anaesthesia maintained during surgery via a nose cone. The skin was cut along the line of the thighbone and the

common sciatic nerve was exposed at the middle of the

thigh by blunt dissection through biceps femoris. Three

ligatures (4-0 silk) were tied loosely around the nerve, the

wound was closed and the animals allowed to recover.

Following surgery the development of static allodynia was

monitored regularly over a period of 4 weeks. Static allo-
dynia was evaluated by application of von Frey hairs

(Stoelting, Wood Dale, Illinois, U.S.A) in ascending order

of force (0.008, 0.02, 0.04, 0.07, 0.16, 0.4, 0.6, 1, 1.4, 2, 4

grams) to the plantar surface of hind paws. Each von Frey

hair was applied to the paw for a maximum of 6 seconds,
or until a withdrawal response occurred. Once a with-
drawal response was established, the paw was re-tested,

starting with the filament below. The lowest amount of

force required to elicit a response was recorded as paw

withdrawal threshold (PWT) in grams. Static allodynia

was defined as present if animals responded to a force
equal to or less than, 0.04 g, which is innocuous in nor-

mal mice. CCI of the rat sciatic nerve was performed as
described previously [21].

**Gene expression analysis**

Mrg family members and genes important for sensory

neuron development and function were quantified in var-

ious tissues from adult WT and MrgE KO mice by quanti-
tative RTPCR analysis. DRG, SC and brain tissues (n = 6)

were harvested from KO and WT mice, stored in RNAlater

(Ambion) at -20 °C. Tissues were mechanically homoge-
nised using Powergen 125 (Fisher) in 600 ul Buffer RLT

(Qiagen) containing β-Mercaptoethanol (10 ul/ml RLT).

SCs and brains were homogenised whole in larger vol-

umes (1.2 ml and 6 ml) accordingly and RNA was

extracted as per the RNeasy tissue protocol (Qiagen) with

on column DNasel treatment. Brains and SCs were also

treated with Amplification Grade DNasel (Invitrogen) in

accordance with the manufacturer’s instructions. RNA was

reverse transcribed using the GeneAmp RNA PCR kit

(Applied Biosystems) and 15 ng/well equivalent of cDNA

used in quantitative PCR TaqMan® to determine gene

expression levels of MrgC11, D, E and G using custom oli-
gos (Sigma) and MrgE, H and PR4 using Assays on

Demand™ (Applied Biosystems). Arbitrary copy number

(ACN) was calculated using the formula ACN = 10(12-

(0.3xCt)). Multiple gene profiling of the DRGs was per-

formed using 1 ng cDNA per well on a custom RT2 PCR

profiler array (SuperArray) and the data analysed using

Spotfire Decision site 8.1. The ACN +/-standard deviation

was calculated as described. Sciatic nerve was harvested

from rats 7, 14 and 21 days post CCI. RNA was isolated

from sciatic nerve ipsilateral and contralateral to the
injured nerve. cDNA was synthesized from isolated sciatic nerve RNA as described for murine RNA. 25 ng/well of cDNA equivalent was used as template in rat MrgE specific TaqMan assays and the data generated analysed using a ΔΔCt method (Applied Biosystems). Ipsilateral versus contralateral levels of MrgE were compared for each time point post surgery and expressed as relative copy number. The sequences of all primers and probes used in this study are available on request.

**Competing interests**

All authors are employees of Pfizer Global Research and Development and may own/ have stock options for Pfizer Inc.

**Authors’ contributions**

TP and CHB performed the pain behavioural tests. SAT performed gene expression studies. WQ was involved in coordination of production and genotyping of KO animals. PJC and RAK conceived of the study, and participated in its design and coordination, and drafted the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

We would like to acknowledge our colleagues Dic Williams and Laura Corradini for helpful suggestions. Mary K. Bauchmann for expanding the ES clones. Jeffrey L. Stock and Diane M.Z. Nadeau for performing blastocyst injection and Janice B. Drummond, Joanne L. Jeffries-Griffor, and Janis O’Quinn Vajdos for genotyping the mice.

**References**

1. Dong X, Han S, Zylko MJ, Simon MI, Anderson DJ: A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell 2001, 106(5):619-632.
2. Grazzini E, Puma C, Roy MO, Yu X, O'Donnell D, Schmidt R, Daudrey S, Duchen MR: Sensory neuron-specific receptor activation elicits central and peripheral nociceptive effects in rats. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(18):7175-7180.
3. Cai M, Chen T, Quirion R, Hong Y: The involvement of spinal bovine adrenal medulla 22-like peptide, the proenkcephalin derivative, in modulation of nociceptive processing. Eur J Neurosci 2007, 26(5):1128-1138.
4. Gustafson EL, Maguire M, Campanella M, Tarozzo G, Jia Y, Dong XW, Laverty M, Murgolo N, Priestley T, Reggiani A, Monsma F, Beltramo M: Regulation of two rat mas-related genes in a model of neuropathic pain. Brain research Molecular brain research 2005, 142(1):58-64.
5. Zylko MJ, Rice FL, Anderson DJ: Topographically distinct epidermal nociceptive circuits revealed by axonal tracers targeted to Mrgprd. Neuron 2005, 45(1):17-25.
6. Crozier RA, Ajit SK, Kafant EJ, Pausch MH: MrgD activation inhibits KCNQ/M-currents and contributes to enhanced neuronal excitability. J Neurosci 2007, 27(16):4492-4496.
7. Chen H, Ikeda SR: Modulation of ion channels and synaptic transmission by a human sensory neuron-specific G-protein-coupled receptor, SNSR4/mrgX1, heterologously expressed in cultured rat neurons. J Neurosci 2004, 24(21):5044-5053.
8. Tatemoto K, Nozaki Y, Tsuda R, Konno S, Tomura K, Furuno M, Ogasawara H, Edamura K, Takagi H, Iwamura H, Noguchi M, Naito T: Immunglobulin E-independent activation of mast cell is mediated by Mrg receptors. Biochem Biophys Res Commun 2006, 349(4):1322-1328.
9. Robas N, Mead E, Fidock M: MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. The Journal of biological chemistry 2003, 278(45):44400-44404.
10. Han SK, Dong X, Hwang JI, Zylko MJ, Anderson DJ, Simon MI: Orphan G protein-coupled receptors MrgA1 and MrgC11 are distinctively activated by RF-amide-related peptides through the Galphai11 pathway. Proc Natl Acad Sci U S A 2002, 99(23):14740-14745.
11. Fukusumi S, Fujii R, Hinuma S: Recent advances in mammalian RFamide peptides: the discovery and functional analyses of PrRP, RFRPs and QRFP. Peptides 2006/02/28 edition. 2006, 27(5):1073-1086.
12. Milasta S, Pediani J, Appelbe S, Trim S, Wyast M, Cox P, Fidock M, Milligan G: Interactions between the Mas-related receptors MrgD and MrgE alter signalling and trafficking of MrgD. Molecular pharmacology 2006, 69(2):479-491.
13. Zhang L, Taylor N, Xie Y, Ford R, Johnson J, Paulsen JE, Bate B: Cloning and expression of Mrg receptors in macaque, mouse, and human. Brain research Molecular brain research 2005, 133(2):187-197.
14. Scholz J, Woolf CJ: The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 2007, 10(11):1361-1368.
15. Zhuo M: Neuronal mechanism for neuropathic pain. Mol Pain 2007, 3:14.
16. Lindfors PH, Väikar V, Rossi J, Airakainen MS: Deficient nonpeptidergic epidermis innervation and reduced inflammatory pain in glial cell line-derived neurotrophic factor family receptor alpha2 knock-out mice. The Journal of Neuroscience: the official journal of the Society for Neuroscience 2006, 26(7):5193-160.
17. Nasser MA, Stirling LC, Fortianni G, Baker MD, Matthews EA, Dickens H, Wood NJ: Nociceptor-specific gene deletion reveals a major role for Nav17 PN1 in acute and inflammatory pain. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(34):12706-12711.
18. Akopian AN, Souaiova V, England S, Okuse K, Ogata N, Ure J, Smith A, Kerr DJ, McMahon SB, Boyce S, Hill R, Stanca L, Dickenson AH, Wood JN: The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nature neuroscience 1999, 2(6):541-548.
19. Laird JMA, Souaiova V, Wood JN, Cervero F: Deficits in visceral pain and referred hyperalgesia in Nav18 SNS /PN3-null mice. The Journal of Neuroscience: the official journal of the Society for Neuroscience 2002, 22(19):8352-8356.
20. Chen CL, Broom DC, Liu Y, de NJC, Li Z, Cen C, Samad OA, Jezell TM, Woolf CJ, Ma Q, Runx1 determines nociceptive sensory neuron phenotype and is required for thermal and neuropathic pain. Neuron 2006, 49(3):365-377.
21. Field MJ, Bramwell S, Hughes J, Singh L: Detection of static and dynamic components of mechanical allodinia in rat models of neuropathic pain: are they signalled by distinct primary sensory neurons? Pain 1999, 83(2):303-311.